<?xml version="1.0" encoding="UTF-8"?>
<p id="par0005">There are only a few available antiviral treatments, which have limited efficacy on COVID-19 at present. The latest Chinese guideline emphasized that convalescent plasma(CP) therapy was an emergent treatment for serious COVID-19 cases [
 <xref rid="bib0005" ref-type="bibr">1</xref>]. Generally, CP has been applied to improve the survival rate of patients with a variety of viral epidemics, including SARS, MERS, influenza, Ebola virus disease, etc [
 <xref rid="bib0010" ref-type="bibr">2</xref>]. More recently, COVID-19 cases have also shown improvement to a certain degree after CP therapy in China [
 <xref rid="bib0015" ref-type="bibr">3</xref>]. In order to take full advantage of this promising treatment, there are still several critical problems need to be clarified.
</p>
